Target Name: CCL11
NCBI ID: G6356
Review Report on CCL11 Target / Biomarker Content of Review Report on CCL11 Target / Biomarker
CCL11
Other Name(s): small inducible cytokine subfamily A (Cys-Cys), member 11 (eotaxin) | Eotaxin-1 | C-C motif chemokine ligand 11 | Small inducible cytokine A11 | SCYA11 | CCL11_HUMAN | Eosinophil chemotactic protein | Small inducible cytokine subfamily A (Cys-Cys), member 11 | C-C motif chemokine 11 | chemokine (C-C motif) ligand 11 | eosinophil chemotactic protein | Eotaxin | eotaxin-1 | Chemokine (C-C motif) ligand 11 | Small-inducible cytokine A11 | Small inducible cytokine subfamily A (Cys-Cys), member 11 (eotaxin)

CCL11: A Promising Drug Target for Immune and Tissue Repair

CCL11, a small inducible cytokine subfamily A member 11, also known as eotaxin, is a protein that plays a critical role in various physiological processes in the body. It is a cytokine that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. CCL11 has been shown to be involved in a wide range of biological processes, including inflammation, cell survival, and tissue repair.

One of the key functions of CCL11 is its ability to induce cell-mediated immunity. It has been shown to stimulate the production of various immune cell types, including T cells, B cells, and natural killer cells. This is important for triggering an immune response to various threats, such as viruses and bacteria.

Another important function of CCL11 is its role in tissue repair and regeneration. It has been shown to promote the growth and differentiation of various cell types, including stem cells and progenitor cells. This is important for wound healing, tissue repair, and regeneration following injury or disease.

In addition to its role in immune and tissue repair processes, CCL11 has also been shown to be involved in various signaling pathways. It has been shown to interact with various signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. This is important for the regulation of various cellular processes, including cell survival, angiogenesis, and inflammation.

Given its involvement in a wide range of biological processes, CCL11 is a promising drug target. Researchers have been exploring the use of various small molecules and other compounds to modulate the activity of CCL11. One of the most promising strategies is the use of small molecules that can inhibit the activity of CCL11 signaling pathways.

One approach to targeting CCL11 is the use of small molecules that can inhibit the activity of its downstream signaling pathways. For example, researchers have used a variety of small molecules to inhibit the activity of CCL11 signaling pathways, including the TGF-β pathway. These small molecules include inhibitors of TGF-β signaling, such as TGF-β inhibitors and inhibitors of the FGF receptor.

Another approach to targeting CCL11 is the use of small molecules that can modulate its activity in a specific manner. For example, researchers have used small molecules to modulate the activity of CCL11 in a dose-dependent manner. This allows researchers to fine-tune the activity of CCL11 and optimize its use as a drug target.

In addition to its potential as a drug target, CCL11 is also a potential biomarker for a variety of diseases. Its role in immune and tissue repair processes makes it an attractive candidate for the development of diagnostic tests for various diseases. For example, CCL11 has been shown to be elevated in the blood of individuals with cancer, and may be a useful biomarker for cancer diagnosis and monitoring.

Overall, CCL11 is a small inducible cytokine subfamily A member 11 that is involved in a wide range of biological processes. Its ability to induce cell-mediated immunity and promote tissue repair and regeneration makes it a promising drug target. The use of small molecules and other compounds to modulate its activity is an promising strategy for the development of new treatments for various diseases.

Protein Name: C-C Motif Chemokine Ligand 11

Functions: In response to the presence of allergens, this protein directly promotes the accumulation of eosinophils, a prominent feature of allergic inflammatory reactions (PubMed:8597956). Binds to CCR3 (PubMed:8631813)

The "CCL11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCL13 | CCL14 | CCL15 | CCL15-CCL14 | CCL16 | CCL17 | CCL18 | CCL19 | CCL2 | CCL20 | CCL21 | CCL22 | CCL23 | CCL24 | CCL25 | CCL26 | CCL27 | CCL28 | CCL3 | CCL3-AS1 | CCL3L1 | CCL3L3 | CCL3P1 | CCL4 | CCL4L1 | CCL4L2 | CCL5 | CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B